when the condition
is serious
IFR Center for Current Research
CRITICAL FINDINGS FROM TOP MEDICAL JOURNALS
|
SearchBreast Cancer: Free Medical and Health Information on Breast Cancer Research and TreatmentBreast Cancer
Search within these results:
Toker cells are epithelial cells with clear cytoplasm usually free of cytologic atypia localized within the nipple epidermis.
Rozzano, Milan Italy HMG-CoA reductase expression in breast cancer is associated with a less aggressive phenotype and inf
Although several studies have reported on the anti-tumoural properties exerted by 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoAR) inhibitors (statins), the in vivo expression of HMG-CoAR in human cancer has been considerably less investigated.
Malmö, Sweden Sweden A number of breast cancer risk factors are modifiable later in life, yet the combined impact of the population changes in these risk factors on breast cancer incidence is not known to have been evaluated.
Madison, WI 53726 USA A hybrid protein comprising ATF domain of pro-UK and VAS, an angiogenesis inhibitor, is a potent can
Directional and controllable degradation of extracellular matrix mediated by the uPA-uPA receptor (uPAR) system is ubiquitously implicated in tumor establishment, invasion and metastasis.
Nanjing, 210093 China Risk of different histological types of postmenopausal breast cancer by type and regimen of menopaus
In a large population-based case-control study in Germany, including 3,464 breast cancer cases aged 50-74 at diagnosis and 6,657 population based and frequency matched controls, we investigated the effects of menopausal hormone therapy (HT) by type, regimen, timing and progestagenic constituent on postmenopausal breast cancer risk overall and according to histological type.
Hamburg, Germany Germany [18F]FDG and [18F]FLT uptake in human breast cancer cells in relation to the effects of chemotherapy
Increased 2'-deoxy-2'-[18F]fluoro-D-glucose (FDG) uptake is the most commonly used marker for positron emission tomography in oncology.
P.O. Box 7057, 1007 MB
Amsterdam, The Netherlands Target and reality of adjuvant endocrine therapy in postmenopausal patients with invasive breast can
Previous research evaluating the use of adjuvant endocrine therapy among postmenopausal breast cancer patients showed with 15-50% wide ranges of non-adherence rates.
Spitalstrasse 21, Basel CH-4031
Switzerland Luteolin as a glycolysis inhibitor offers superior efficacy and lesser toxicity of doxorubicin in br
Luteolin (Lu) exhibits a wide spectrum of anti-tumor activities, the present study was to observe whether Lu can sensitize breast cancer cells to doxorubicin (Dox) and to explain the basis underlying this phenomenon.
Jinming District, Kaifeng, Henan
475001 China Percutaneous tissue acquisition: a treatment for breast cancer? Vacuum-assisted biopsy devices are n
Quite a number of radiologists indicate that complete removal of an imaged lesion in the breast by transdermal tissue acquisition is beneficial for the patient.
Liège, Belgium The Netherlands Six genes confer a high risk for developing breast cancer (BRCA1/2, TP53, PTEN, STK11, CDH1). Both BRCA1 and BRCA2 have DNA repair functions, and BRCA1/2 deficient tumors are now being targeted by poly(ADP-ribose) polymerase inhibitors.
Montreal, Quebec Canada |
PartnersLinksApproved By
|
